Blood metabolic signatures of hikikomori, pathological social withdrawal

Dialogues Clin Neurosci. 2022 Jun 1;23(1):14-28. doi: 10.1080/19585969.2022.2046978. eCollection 2021.

Abstract

Background: A severe form of pathological social withdrawal, 'hikikomori,' has been acknowledged in Japan, spreading worldwide, and becoming a global health issue. The pathophysiology of hikikomori has not been clarified, and its biological traits remain unexplored.

Methods: Drug-free patients with hikikomori (n = 42) and healthy controls (n = 41) were recruited. Psychological assessments for the severity of hikikomori and depression were conducted. Blood biochemical tests and plasma metabolome analysis were performed. Based on the integrated information, machine-learning models were created to discriminate cases of hikikomori from healthy controls, predict hikikomori severity, stratify the cases, and identify metabolic signatures that contribute to each model.

Results: Long-chain acylcarnitine levels were remarkably higher in patients with hikikomori; bilirubin, arginine, ornithine, and serum arginase were significantly different in male patients with hikikomori. The discriminative random forest model was highly performant, exhibiting an area under the ROC curve of 0.854 (confidential interval = 0.648-1.000). To predict hikikomori severity, a partial least squares PLS-regression model was successfully created with high linearity and practical accuracy. In addition, blood serum uric acid and plasma cholesterol esters contributed to the stratification of cases.

Conclusions: These findings reveal the blood metabolic signatures of hikikomori, which are key to elucidating the pathophysiology of hikikomori and also useful as an index for monitoring the treatment course for rehabilitation.

Keywords: COVID-19; Hikikomori; acylcarnitine; plasma metabolome; social isolation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Japan
  • Male
  • Phobia, Social*
  • Shame
  • Social Isolation* / psychology
  • Uric Acid

Substances

  • Uric Acid

Supplementary concepts

  • hikikomori

Grants and funding

This study was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS KAKENHI Grant Numbers JP16H06403, JP18H04042, JP19K21591, JP20H01773 to T.A.K. and JP18K07417 and JP21K07369 to D.S.), and the Japan Agency for Medical Research and Development (AMED) (JP19dk0307047, JP19dk0307075, JP19dm0107095, and JP21wm0425010 to T.A.K.).